1. Introduction {#sec1-molecules-24-01654}
===============

Thiazoline-based compounds possess a variety of biological activities such as antiproliferative \[[@B1-molecules-24-01654],[@B2-molecules-24-01654],[@B3-molecules-24-01654],[@B4-molecules-24-01654],[@B5-molecules-24-01654],[@B6-molecules-24-01654],[@B7-molecules-24-01654],[@B8-molecules-24-01654],[@B9-molecules-24-01654],[@B10-molecules-24-01654]\], anti-inflammatory \[[@B11-molecules-24-01654]\], antimicrobial, \[[@B12-molecules-24-01654]\] and antioxidant properties \[[@B13-molecules-24-01654]\]. In addition, they are reported as butyrylcholinesterase and carboxylesterase inhibitors \[[@B14-molecules-24-01654]\]. Motivated by the above-mentioned results, numerous design and synthesis efforts have been employed to develop new derivatives with more effective and safer therapeutic profiles \[[@B15-molecules-24-01654],[@B16-molecules-24-01654],[@B17-molecules-24-01654],[@B18-molecules-24-01654],[@B19-molecules-24-01654],[@B20-molecules-24-01654],[@B21-molecules-24-01654],[@B22-molecules-24-01654],[@B23-molecules-24-01654],[@B24-molecules-24-01654],[@B25-molecules-24-01654],[@B26-molecules-24-01654],[@B27-molecules-24-01654],[@B28-molecules-24-01654],[@B29-molecules-24-01654],[@B30-molecules-24-01654]\]. Additionally, heterocycles based on a thiazoline-2-thione core may undergo several chemical reactions, including alkylation, oxidation, and cycloaddition, as a result of having two different nitrogenous and sulfurous groups \[[@B31-molecules-24-01654],[@B32-molecules-24-01654],[@B33-molecules-24-01654],[@B34-molecules-24-01654],[@B35-molecules-24-01654],[@B36-molecules-24-01654],[@B37-molecules-24-01654]\]. There are many methods for preparing thiazoline-2-thione derivatives from alkyl ammonium dithiocarbamates with the appropriate α-halocompound in the presence of an acid \[[@B38-molecules-24-01654],[@B39-molecules-24-01654],[@B40-molecules-24-01654],[@B41-molecules-24-01654],[@B42-molecules-24-01654]\] or by using primary amines, CS~2~ and α-haloketone in DMF \[[@B43-molecules-24-01654]\] or toluene \[[@B44-molecules-24-01654]\] or in water as a solvent \[[@B45-molecules-24-01654]\], or without solvent or catalyst \[[@B46-molecules-24-01654]\]. These findings encouraged us to conduct a slightly modification of the reported reaction condition \[[@B45-molecules-24-01654],[@B47-molecules-24-01654],[@B48-molecules-24-01654]\] to synthesize new thiazoline derivatives and to investigate their synthetic potential in the preparation of new thiazoline based heterocycles in order to assess their biological activities.

2. Results and Discussion {#sec2-molecules-24-01654}
=========================

2.1. Chemistry {#sec2dot1-molecules-24-01654}
--------------

The first series consisted of stirring 3-chloropentane-2,4-dione (**1a**) or ethyl 2-chloro-3-oxobutanoate (**1b**) with the appropriate primary amine and carbon disulfide in ethanol at room temperature; this afforded the target thiazoline-2-thione derivatives **2a**--**e** in high yields ([Scheme 1](#molecules-24-01654-sch001){ref-type="scheme"}).

The suggested mechanism for their synthesis is illustrated in [Scheme 2](#molecules-24-01654-sch002){ref-type="scheme"}. In this mechanism, the treatment of aniline with carbon disulfide results ammonium dithiocarbamate **3**, which reacts with α-halo-1,3-diketone **1** to produce acyclic dithiocarbamate derivative **4**. Intramolecular cyclization of intermediate **4**, followed by dehydration, yields the target compounds **2a**--**e** ([Scheme 2](#molecules-24-01654-sch002){ref-type="scheme"}).

The structures of the obtained products **2a**--**e** were established and confirmed via spectroscopic (NMR, MS, IR) and elemental analyses. Their ^1^H-NMR spectra showed the presence of a singlet signal due to methyl protons at carbon 4, in addition to the other expected proton signals. In addition, their ^13^C-NMR spectra confirmed the assigned structures and revealed the presence of the expected signals of carbonyl and thiocarbonyl at δ 177.5--188.17 and δ 190.0--193.18, respectively (see the Materials and Methods section). It is important to note that compounds **2a**--**d** were prepared by another two methods as follows: (i) in 54% and 74% yield, respectively, by using the same reagents as for compounds **2a**,**b** in the presence of NaOH as basic catalyst \[[@B47-molecules-24-01654]\]; (ii) in yields of 74% and 75%, respectively, by the second literature method for synthesis of derivatives **2c**,**d** from α-halo-compounds with ammonium dithiocarbamate \[[@B48-molecules-24-01654]\]. Our method for synthesis of compounds **2a**--**e** features better yields of these compounds.

Refluxing compound **2a** with the appropriate aniline derivatives afforded a new series of thiazoline derivatives, **5a**--**e**, as shown in [Scheme 3](#molecules-24-01654-sch003){ref-type="scheme"}. The structures of the target products **5a**--**e** were deduced from their IR, NMR and mass spectra. For example, their IR spectra revealed the absence of any absorption band due to the carbonyl group, which was apparent in compound **2a**. Also, the ^13^C-NMR spectra of the synthesized products **5a**--**e** showed, in each case, the absence of the carbonyl signal (see the Materials and Methods section). Moreover, the structure of **5c**, as a typical example of the prepared series, was confirmed by single crystal X-ray analysis ([Figure 1](#molecules-24-01654-f001){ref-type="fig"}).

Next, the reaction of the thiazoline-2-thione derivative **2a** \[[@B45-molecules-24-01654],[@B47-molecules-24-01654]\] with 2-oxo-*N*′-phenylpropane hydrazonoyl chloride (**6**) \[[@B49-molecules-24-01654],[@B50-molecules-24-01654]\] produced the spiro-compound **7 \[[@B51-molecules-24-01654]\]** ([Scheme 3](#molecules-24-01654-sch003){ref-type="scheme"}). The reaction was assumed to proceed via a 1,3-dipolar cycloaddtion reaction between nitrile imine (formed in situ from hydrazonoyl halide **6** by the action of triethylamine) and C=S of thiazoline-2-thione derivative **2a**. The ^1^H-NMR spectrum of spiro-compound **7** presented three signals at δ 1.92, 2.10 and 2.22, corresponding to three sets of methyl group protons. Additionally, its spectrum showed signals of the phenyl ring in the 7.35--7.59 ppm region. Also, the signal of C=S disappeared in its ^13^C-NMR spectrum.

2.2. X-ray Analysis {#sec2dot2-molecules-24-01654}
-------------------

The crystallographic data of thiazoline derivative **5c** and the refinement information are summarized in [Table 1](#molecules-24-01654-t001){ref-type="table"}. The selected bond lengths and bond angles are listed in [Table 2](#molecules-24-01654-t002){ref-type="table"}. The asymmetric unit contains one independent molecule, as shown in [Figure 1](#molecules-24-01654-f001){ref-type="fig"}. All the bond lengths and angles are in normal ranges \[[@B52-molecules-24-01654]\]. In the crystal packing, shown in [Figure 2](#molecules-24-01654-f002){ref-type="fig"}, molecules are linked via one intermolecular hydrogen bond ([Table 3](#molecules-24-01654-t003){ref-type="table"}).

The Crystallographic data for thiazoline **5c** (CCDC Number 1818811) can be obtained on request from the director, Cambridge Crystallographic Data Center, 12 Union Road, Cambridge CB2 1EW, UK.

2.3. Biological Evaluation {#sec2dot3-molecules-24-01654}
--------------------------

### 2.3.1. The In Vitro Antimicrobial Assessment of the Synthesized Thiazolines {#sec2dot3dot1-molecules-24-01654}

The antifungal and antibacterial potency of the synthesized compounds and the reference drugs were evaluated against two fungal species (*Aspergillus fumigatus* (RCMB 002008 (4) and *Candida albicans* (RCMB 05036)), two gram positive bacteria *(Staphylococcus aureus* (RCMB010010) and *Bacillus subtilis* (RCMB 010067)), and two gram negative bacteria (*Salmonella* sp. (RCMB 010043) and *Escherichia coli* (RCMB 010052)) using the inhibition zone technique according to the reported methods \[[@B53-molecules-24-01654],[@B54-molecules-24-01654]\]. The results of this assessment are depicted in [Table 4](#molecules-24-01654-t004){ref-type="table"}. Tests indicate that the compounds **2c**, **2d**, **2e**, and **5d** had significant antifungal activity against *Aspergillus fumigatus*. Additionally, all the evaluated thiazolines, except **2b**, were effective against *Candida albicans*. The study also showed that the tested compounds had important biological effectiveness against *Staphylococcus aureus* and *Bacillus subtilis* (except **2b**). The evaluation results showed that all the test compounds were effective against *Salmonella* sp., particularly **2c**, **5b** and **5d**; they approach the potency of Gentamycin. Moreover, the inhibition potency of thiazolines **2e** and **5b** is similar to the potency of Gentamycin towards *Escherichia coli*.

### 2.3.2. Molecular Docking {#sec2dot3dot2-molecules-24-01654}

The docking study play important role in predicting with the biological activity of any compounds. So, this study is considered a key for design and manufacturing of new drugs. We selected two derivatives **2c** and **5b** from the two synthesized series to use in molecular docking to study their behavior and their mode of action. Both thiazoline derivatives **2c** and **5b** were docked with human cyclin-dependent kinase enzyme (CDK 2), one of the kinase family, due to their important role in cell meiosis and replication.

Molecular docking was implemented using the MOE 2014.010 Package software. The structure of CDK2 was obtained from a protein data bank. Protein was optimized by adding hydrogen, repairing broken amino acid residues and removing water. In addition, compounds **2c** and **5b** were optimized for docking by adding hydrogen and then forcing energy minimization.

The binding affinity of thiazoline **2c** showed hydrogen acceptor interactions with **Thr 14** and **Lys 129**, with binding energies equal −4 (kcal/mol). Also, it exhibited a pi-hydrogen interaction with **Gly 13**, with binding energy equal −0.6 (kcal/mol) ([Figure 3](#molecules-24-01654-f003){ref-type="fig"}).

In contrast, thiazoline derivative **5b** had less binding affinity to the CDK 2 enzyme than compound **2c**. It showed only one pi-hydrogen interaction with **Glu 12**, with binding energy equal -0.1 (kcal/mol) ([Figure 4](#molecules-24-01654-f004){ref-type="fig"}).

### 2.3.3. Antitumor Evaluation of Some Selected Examples of the Synthesized Compounds {#sec2dot3dot3-molecules-24-01654}

The in vitro antitumor activity of some selected examples of the synthesized thiazolines and the reference drug Doxorubicin were investigated using the MTT method \[[@B55-molecules-24-01654]\] against human hepatocellular carcinoma cell line (HepG-2) and colon carcinoma cells (HCT-116). The concentration of the tested thiazolines needed to inhibit 50% of the cells population (IC~50~) was calculated and is presented in [Table 5](#molecules-24-01654-t005){ref-type="table"} and [Table 6](#molecules-24-01654-t006){ref-type="table"} and [Figure 5](#molecules-24-01654-f005){ref-type="fig"} and [Figure 6](#molecules-24-01654-f006){ref-type="fig"}.

The results of [Table 5](#molecules-24-01654-t005){ref-type="table"} and [Table 6](#molecules-24-01654-t006){ref-type="table"} showed that the tested thiazolines **5b** and **2c** have the highest effectiveness compared to the other thiazoline derivatives against the HepG-2 and HCT-116 cell lines, with IC~50~ values of approximately 7.46 µg/mL and 27.9 µg/mL for HepG-2 and 12.6 µg/mL and 29.1 µg/mL, for HCT-116, respectively. The remaining compounds have a noticeably moderated efficiency.

3. Materials and Methods {#sec3-molecules-24-01654}
========================

3.1. Chemistry {#sec3dot1-molecules-24-01654}
--------------

### 3.1.1. General Information {#sec3dot1dot1-molecules-24-01654}

All the melting points were measured using a Gallenkamp apparatus (Thermo Fisher Scientific, Paisley, UK) in open glass capillaries and are uncorrected. Infrared spectra (IR) were recorded using the KBr disc technique on a Perkin Elmer FT-IR spectrophotometer 1000 (PerkinElmer, Waltham, MA, USA). NMR spectra (^1^H and ^13^C) were measured using an ECP 400 NMR spectrometer (JEOL, Tokyo, Japan) operating at 400 MHz in deuterated chloroform (CDCl~3~). Mass spectra were measured on a Shimadzu GCMS-QP 1000 EX mass spectrometer (Tokyo, Japan) at 70 eV. Elemental analysis were recorded on a 2400 CHN Elemental Analyzer. The single-crystal X-ray diffraction measurements were done on a SMART APEX II CCD diffractometer (Bruker AXS Advanced X-ray Solutions GmbH, Karlsruhe, Germany). The biological assessments of the synthesized compounds were done in the Medical Mycology Laboratory of the Regional Center for Mycology and Biotechnology of Al-Azhar University, Cairo, Egypt. The 2-oxo-*N*′-phenylpropanehydrazonoyl chloride (**6**) was prepared as described in the literature \[[@B49-molecules-24-01654],[@B50-molecules-24-01654]\].

### 3.1.2. The Synthetic Procedure for the Target Thiazolines **2a**--**e** {#sec3dot1dot2-molecules-24-01654}

To a solution of 3-chloropentane-2,4-dione (0.134 g, 0.112 mL, 1 mmol) or ethyl 2-chloro-3-oxobutanoate (0.164 g, 0.138 mL, 1 mmol) in ethanol (15 mL), carbon disulfide (0.152 g, 0.12 mL, 2 mmol) and the appropriate amine derivative (1 mmol) were added. The reaction mixture was stirred for six hours. The solid product that formed was filtered and washed with ethanol, and recrystallized to afford the corresponding thiazolines **2a**--**e**. The physical properties and spectroscopic data of compounds **2a**--**d** are in agreement with the literature \[[@B45-molecules-24-01654],[@B47-molecules-24-01654],[@B48-molecules-24-01654]\].

*1-(4-Methyl-3-phenyl-2-thioxo-2,3-dihydrothiazol-5-yl)ethan-1-one* (**2a**): Yellow solid, (0.23 g, yield 92%); m.p. 172--174 °C (EtOH) \[lit mp. 171--174 °C \[[@B45-molecules-24-01654],[@B47-molecules-24-01654]\]\]; IR v~max~ 1630 (C=O), 1490 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 2.25 (s, 3H, CH~3~), 2.35 (s, 3H, CH~3~), 7.14--7.52 (m, 5H, Ph); ^13^C-NMR (CDCl~3~) δ 16.14, 30.23 (2CH~3~), 112.50, 147.34, 121.50, 128.05, 130.16, 137.08, 188.17, 190.00. Anal. Calcd. for C~12~H~11~NOS~2~ (249.35): C, 57.80; H, 4.45; N, 5.62. Found: C, 57.91; H, 4.52; N, 5.55%.

*Ethyl 4-methyl-3-phenyl-2-thioxo-2,3-dihydrothiazole-5-carboxylate* (**2b**): white powder, (0.24 g, yield 85%); m.p. 160--162 °C (EtOH) \[lit. mp. 158--160 °C \[[@B47-molecules-24-01654]\]\]; IR v~max~ 1698 (C=O), 1621 (C=C), 1514 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.29 (t, 3H, CH~3~), 2.25 (s, 3H, CH~3~), 4.25 (q, 2H, CH~2~), 7.15--7.53 (m, 5H, Ph); MS (*m/z*) (%) 279 (M^+^, 100%), 278 (54%), 250 (59%), 234 (12%). Anal. Calcd. for C~13~H~13~NO~2~S~2~ (279.38): C, 55.89; H, 4.69; N, 5.01. Found: C, 55.82; H, 4.73; N, 5.10%.

*1-(4-Methyl-2-thioxo-2,3-dihydrothiazol-5-yl)ethanone* (**2c**): white powder, (0.147 g, yield 85%); m.p. 208--210 °C (EtOH) \[lit. mp. 210--211 °C \[[@B48-molecules-24-01654]\]\]; IR v~max~ 3210 (NH), 1669 (C=O), 1617(C=C), 1537(C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.77 (s, 3H, CH~3~), 2.35 (s, 3H, CH~3~), 7.2 (s, H, NH); ^13^C-NMR (CDCl~3~) δ 17.70 (CH~3~), 25.60 (CH~3~), 119.00, 148.00, 188.00, 192.00; MS (*m/z*) (%) 173 (M^+^, 2%), 43 (34%). Anal. Calcd. for C~6~H~7~NOS~2~ (173.26): C, 41.59; H, 4.07; N, 8.08. Found: C, 41.63; H, 4.14; N, 8.12%.

*Ethyl 4-methyl-2-thioxo-2,3-dihydrothiazole-5-carboxylate* (**2d**): white powder, (0.152 g, yield 75%); m.p. 146--148 °C (EtOH) \[lit. mp. 151--152 °C \[[@B48-molecules-24-01654]\]\]; IR v~max~ 3383 (NH), 1674 (C=O), 1601 (C=C), 1425 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.36 (t, 3H, CH~3~), 2.49 (s, 3H, CH~3~), 4.35 (q, 2H, CH~2~), 7.19 (s, H, NH); ^13^C-NMR (CDCl~3~) δ 14.22 (CH~3~), 29.34 (CH~3~), 61.94 (CH~2~), 118.50, 162.81, 177.50, 193.18; MS (*m/z*) (%) 204 (16%), 203 (M^+^, 70%), 159 (99%), 158 (30%), 43 (100%). Anal. Calcd. for C~7~H~9~NO~2~S~2~ (203.28): C, 41.36; H, 4.46; N, 6.89. Found: C, 41.42; H, 4.53; N, 6.78%.

*Ethyl 4-methyl-3-(phenylamino)-2-thioxo-2,3-dihydrothiazole-5-carboxylate* (**2e**): white powder, (0.25 g, yield 85%); mp 210--212 °C (EtOH); IR v~max~ 3390 (NH), 1701 (C=O), 1593 (C=C), 1544 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.33 (t, 3H, CH~3~), 2.45 (s, 3H, CH~3~), 4.30 (q, 2H, CH~2~), 7.21--7.69 (m, 5H, ArH), 11.85 (s, 1H, NH); MS (*m/z*) (%) 294 (M^+^, 1%), 248 (6%), 216 (80%), 77 (100). Anal. Calcd. for C~13~H~14~N~2~O~2~S~2~ (294.39): C, 53.04; H, 4.79; N, 9.52. Found: C, 53.12; H, 4.84; N, 9.43%.

### 3.1.3. Synthetic Procedure for Substituted 4-Methyl-3-Phenylthiazole-2(3*H*)-Thione **5a**--**e** {#sec3dot1dot3-molecules-24-01654}

A mixture of the appropriate amine (1 mmol) and thiazoline **2a** (0.249 g, 1 mmol) in ethanol (10 mL) was refluxed for approximately six hours until the precipitation was produced. Then, the product was filtered and recrystallized from ethanol to afford the corresponding condensation product.

*5-(1-Hydrazonoethyl)-4-methyl-3-phenylthiazole-2(3H)-thione* (**5a**): Yellow powder, (0.145 g, yield 55%); m.p. 215--217 °C (EtOH); IR v~max~ 3208, 3160 (NH~2~), 1631 (C=N), 1487 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.99 (s, 3H, CH~3~), 2.49 (s, 3H, CH~3~), 6.65 (s, 2H, NH~2~), 7.30--7.60 (m, 5H, Ph); MS (*m/z*) (%) 264 (22%), 263 (M^+^, 82%),77(100%). Anal. Calcd. for C~12~H~13~N~3~S~2~ (263.38): C, 54.72; H, 4.97; N, 15.95. Found: C, 54.68; H, 4.87; N, 15.88%.

*4-Methyl-3-phenyl-5-(1-(phenylimino)ethyl)thiazole-2(3H)-thione* (**5b**): Yellow powder, (0.162 g, yield 50%; m.p. 228--230 °C (EtOH); IR v~max~ 1590 (C=N), 1492 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.95 (s, 3H, CH~3~), 2.17 (s, 3H, CH~3~), 7.30-7.59 (m, 10H, Ph); MS (*m/z*) (%) 324 (M^+^, 2%), 247 (24%), 77(100%). Anal. Calcd. for C~18~H~16~N~2~S~2~ (324.46): C, 66.63; H, 4.97; N, 8.63. Found: C, 66.55; H, 4.83; N, 8.55%.

*(E)-4-Methyl-3-phenyl-5-(1-(2-phenylhydrazono)ethyl)thiazole-2(3H)-thione* (**5c**): Yellow powder, (0.203 g, yield 60%); m.p. 220--222 °C (EtOH); IR v~max~ 3289 (NH), 1589 (C=N), 1495 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 2.08 (s, 3H, CH~3~), 3.32 (s, 3H, CH~3~), 7.12--7.58 (m, 10H, ArH), 9.51 (s, 1H, NH); ^13^C-NMR (CDCl~3~) δ 15.38 (CH~3~), 15.71 (CH~3~), 112.71, 137.96, 119.31, 124.02, 123.81, 128.57, 128.96, 134.30, 135.47, 137.96, 145.27, 186.91; MS (*m/z*) (%) 340 (20%), 339 (M^+^, 96%), 247 (14%), 77(100%). Anal. Calcd. for C~18~H~17~N~3~S~2~ (339.48): C, 63.68; H, 5.05; N, 12.38. Found: C, 63.73; H, 5.12; N, 12.29%.

*5-(1-((1H-1,2,4-Triazol-5-yl)imino)ethyl)-4-methyl-3-phenylthiazole-2(3H)-thione* (**5d**): Yellow powder, (0.158 g, yield 50%); m.p. 275--277 °C (DMF); IR v~max~ 3370 (NH), 1637 (C=N), 1577(C=C), 1470 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.95 (s, 3H, CH~3~), 2.20 (s, 3H, CH~3~), 7.30-7.62 (m, 6H, Ph), 8.72 (s, 1H, NH); MS (*m/z*) (%) 315 (M^+^, 6%), 300 (10%), 105 (68%). Anal. Calcd. for C~14~H~13~N~5~S~2~ (315.42): C, 53.31; H, 4.15; N, 22.20. Found: C, 53.28; H, 4.22; N, 22.12%.

*5-(1-((1H-Benzo\[d\]imidazol-2-yl)imino)ethyl)-4-methyl-3-phenylthiazole-2(3H)-thione* (**5e**): Yellow powder, (0.164 g, yield 45%); m.p. 200--202 °C (EtOH); IR v~max~ 3236 (NH), 1586 (C=C), 1487 (C=S) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.90 (s, 3H, CH~3~), 2.25 (s, 3H, CH~3~), 7.20--7.61 (m, 9H, Ph), 11.62 (s, 1H, NH); MS (*m/z*) (%) 364 (M^+^, 8%), 249 (52%), 248 (36%), 133 (98%), 43 (100%). Anal. Calcd. for C~19~H~16~N~4~S~2~ (364.49): C, 62.61; H, 4.42; N, 15.37. Found: C, 62.55; H, 4.38; N, 15.42%.

### 3.1.4. 3,7-Diacetyl-8-methyl-1,9-diphenyl-4,6-dithia-1,2,9-triazaspiro\[4.4\]nona-2,7-diene (**7**) {#sec3dot1dot4-molecules-24-01654}

To a mixture of thiazole derivative **2a** (0.249g, 1 mmol) and 2-oxo-*N*′-phenylpropane hydrazonoyl chloride (**6**) (0.196 g, 1 mmol) in dry benzene (10 mL), triethylamine (0.2 g, 0.28 mL, 2 mmol) was added and the reaction mixture was heated under reflux for 6 h. The precipitated triethylamine hydrochloride was removed by filtration and the filterate was evaporated under a vacuum. The remaining residue was treated using ethanol and the solid product that formed was filtered off and recrystallized using ethanol to give the spiro-compound **7**. Yellowish powder, (0.204 g, yield 50%); m.p. 154--156 °C (DMF)\[Lit mp. 155--157 °C (MeCN)\] \[[@B51-molecules-24-01654]\]\]; IR v~max~ 1644 (C=O), 1549 (C=C) cm^−1^; ^1^H-NMR (CDCl~3~) δ 1.92 (s, 3H, CH~3~), 2.10 (s, 3H, CH~3~), 2.22 (s, 3H, CH~3~), 7.35--7.59 (m, 10H, Ph); MS (*m/z*) (%) 409 (M^+^, 2%), 43 (100%). Anal. Calcd. for C~21~H~19~N~3~O~2~S~2~ (409.52): C, 61.59; H, 4.68; N, 10.26. Found: C, 61.66; H, 4.73; N, 10.22%.

3.2. X-ray Analysis {#sec3dot2-molecules-24-01654}
-------------------

The thiazoline derivative **5c** was obtained as single crystals by slow evaporation from an ethanol solution of the pure compound at room temperature. The thiazoline structure was evaluated using SHELXT \[[@B56-molecules-24-01654],[@B57-molecules-24-01654]\]. All the crystallographic data of the crystal structure **5c** are available and can be obtained free of charge from the Cambridge Crystallographic Data Centre via [www.ccdc.cam.ac.uk/data_request/cif](www.ccdc.cam.ac.uk/data_request/cif). For additional details, refer to the [Supplementary Materials file](#app1-molecules-24-01654){ref-type="app"}.

3.3. Biological Evaluations {#sec3dot3-molecules-24-01654}
---------------------------

### 3.3.1. The In Vitro Antimicrobial Investigation {#sec3dot3dot1-molecules-24-01654}

The antimicrobial activities of the newly synthesized thiazolines were evaluated by the inhibition zone technique on *Aspergillus fumigatus*, *Candida albicans*, *Staphylococcus aureus*, *Bacillus subtilis*, *Salmonella* sp. and *Escherichia coli* \[[@B53-molecules-24-01654],[@B54-molecules-24-01654]\]. Additional details are available in the [Supplementary Materials file](#app1-molecules-24-01654){ref-type="app"}.

### 3.3.2. In Vitro Cytotoxic Activity {#sec3dot3dot2-molecules-24-01654}

The cytotoxic assessment of the target thiazole derivatives was carried out against two cancer cell lines (HepG2 and HCT-116) using the MTT assay after 24 h of incubation \[[@B55-molecules-24-01654]\]. The experimental procedure is included in the [Supplementary Materials file](#app1-molecules-24-01654){ref-type="app"}.

3.4. Molecular Modeling {#sec3dot4-molecules-24-01654}
-----------------------

The docking study was performed using the MOE 2014.09 software \[[@B58-molecules-24-01654]\]. Regularization and optimization for the protein and ligand were performed. Each docked thiazole was assigned a score according to its fit in the ligand binding pocket (LBP) and its binding mode.

4. Conclusions {#sec4-molecules-24-01654}
==============

In this work, new thiazolines were prepared, characterized and evaluated for their biological activities. The results of the antimicrobial evaluation indicated that the thiazoline derivatives **2c**, **5b** and **5e** exhibited high inhibitory activity against *Salmonella* sp., while compounds **2e** and **5b** were comparable to Gentamycin against *Escherichia coli*. The data from the in vitro antitumor evaluation revealed that the thiazolines **5b** and **2c** were the most effective against the HepG-2 and HCT-116 cell lines. This remarkable efficacy has potential usage in numerous pharmaceutical applications. Molecular docking study supported anticancer results and showed binding affinities for thiazolines **5b** and **2c** towards cyclin-dependant kinase 2.
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![Synthesis of the target thiazoline-2-thiones **2a**--**e**.](molecules-24-01654-sch001){#molecules-24-01654-sch001}

![A suggested mechanism for the synthesis of target compounds **2a**--**e**.](molecules-24-01654-sch002){#molecules-24-01654-sch002}

![Synthesis of thiazoline drivatives **5a**--**e**, **7**, and **8**.](molecules-24-01654-sch003){#molecules-24-01654-sch003}

![ORTEP diagram of the thiazoline **5c**. Displacement ellipsoids are plotted at the 40% probability level for non-H atoms.](molecules-24-01654-g001){#molecules-24-01654-f001}

![Molecular packing of thiazoline **5c** viewed hydrogen bonds, which are drawn as dashed lines along a axis.](molecules-24-01654-g002){#molecules-24-01654-f002}

![Thiazoline **2c** into the binding pocket of CDK 2 enzyme showing the binding energies and interactions with amino acid residues.](molecules-24-01654-g003){#molecules-24-01654-f003}

![Thiazoline **5b** into the binding pocket of CDK 2 enzyme showing the binding energies and interactions with amino acid residues.](molecules-24-01654-g004){#molecules-24-01654-f004}

![The viability values of the most active thiazolines against HepG-2 cell line.](molecules-24-01654-g005){#molecules-24-01654-f005}

![The viability values of the most active thiazoline derivatives against HCT-116 cell line.](molecules-24-01654-g006){#molecules-24-01654-f006}
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###### 

The crystal and experimental data of thiazoline **5c**.

  ---------------------------------------------------------------------- -------------------------------------------------------------------------
  **Crystal Data**                                                       
  Chemical formula                                                       C~18~H~17~N~3~S~2~
  Mr                                                                     339.46
  Crystal system, space group                                            Monoclinic, *Pc*
  Temperature (K)                                                        293
  *a*, *b*, *c* (Å)                                                      9.2105 (4), 7.4969 (3), 12.9869 (5)
  β (°)                                                                  109.440 (2)
  V (Å^3^)                                                               845.62 (6)
  *Z*                                                                    2
  Radiation type                                                         Cu *K*α
  µ (mm^−1^)                                                             2.86
  Crystal size (mm)                                                      0.42 × 0.35 × 0.32
  **Data Collection**                                                    
  Diffractometer                                                         Bruker APEX-II D8 venture diffractometer
  Absorption correction                                                  Multi-scan SADABS Bruker 2014
  T~min~, T~max~                                                         0.884, 0.909
  No. of measured, independent and observed \[I \> 2σ(I)\] reflections   8683, 3089, 2993
  R~int~                                                                 0.039
  **Refinement**                                                         
  R\[*F^2^* \> 2σ( *F^2^*)\], wR( *F^2^*), S                             0.030, 0.075, 1.07
  No. of reflections                                                     3089
  No. of parameters                                                      214
  No. of restraints                                                      2
  H-atom treatment                                                       H atoms treated by a mixture of independent and constrained refinement
  Δρ~max~, Δρ~min~ (e Å^−3^)                                             0.20, −0.32
  Absolute structure                                                     Flack x determined using 1376 quotients \[(I+) − (I)\]/ \[(I+) + (I−)\]
  Flack parameter                                                        0.031 (9)
  ---------------------------------------------------------------------- -------------------------------------------------------------------------
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###### 

Selected geometric parameters (Å) of thiazoline **5c**.

  --------------- ------------- ---------------- -----------
  S1---C1         1.722 (3)     N1---C4          1.447 (4)
  S1---C2         1.748 (3)     N2---N3          1.363 (4)
  S2---C1         1.668 (3)     N2---C11         1.289 (4)
  N1---C1         1.363 (4)     N3---C13         1.390 (4)
  N1---C3         1.413 (4)                      
  C1---S1---C2    92.77 (14)    S1---C2---C11    116.7 (2)
  C1---N1---C3    115.5 (2)     N1---C3---C2     112.2 (3)
  C1---N1---C4    121.2 (3)     N1---C3---C10    118.1 (3)
  C3---N1---C4    123.3 (2)     N1---C4---C5     118.0 (3)
  N3---N2---C11   119.6 (3)     N1---C4---C9     120.2 (2)
  N2---N3---C13   118.4 (3)     N2---C11---C2    112.3 (3)
  S1---C1---N1    109.1 (2)     N2---C11---C12   125.7 (3)
  S2---C1---N1    127.2 (2)     N3---C13---C14   118.1 (3)
  S1---C1---S2    123.69 (17)   N3---C13---C18   122.5 (3)
  S1---C2---C3    110.4 (2)                      
  --------------- ------------- ---------------- -----------
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###### 

Hydrogen-bond geometry (Å) of thiazoline **5c**.

  D---H···A                                     D···A       D---H···A
  --------------------------------------------- ----------- -----------
  N3---H1···S2^i^                               3.579 (3)   144 (3)
  Symmetry codes: (i) x − 1, −y + 1, z − 1/2.               
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###### 

The in vitro antimicrobial assessment of the synthesized compounds expressed as inhibition zones diameter in millimeters (mm).

  Sample               Microorganisms                       
  -------------------- ---------------- ---- ---- ---- ---- ----
  **2b**               NA               NA   NA   NA   11   8
  **2c**               14               13   15   12   15   14
  **2d**               10               13   13   10   13   14
  **2e**               15               15   13   14   13   17
  **5a**               NA               13   9    9    13   12
  **5b**               NA               13   9    10   14   16
  **5c**               NA               12   9    9    12   10
  **5d**               13               17   13   12   14   13
  **5e**               NA               14   8    9    13   9
  **Amphotericin B**   23               25   \-   \-   \-   \-
  **Ampicillin**                             23   32   \-   \-
  **Gentamycin**       \-               \-   \-   \-   17   19

NA: No activity; results of the antimicrobial evaluation are expressed as mean of inhibition zone diameter (mm) for different compounds tested in triplicate; *Aspergillus fumigatus (RCMB 002008 (4)* (AF), *Candida albicans (RCMB 05036) (CA*), *Staphylococcus aureus (RCMB010010) (SA*), *Bacillus subtilis (RCMB 010067)* (*BS*), *Salmonella sp. (RCMB 010043) (SSP*), *Escherichia coli* *(RCMB 010052* *(EC)*.
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###### 

Viability values and IC~50~ of tested thiazolines and control drug *Doxorubicin* against *hepatocellular carcinoma cell line (HepG-2)*.

  Sample Number                Sample Concentration (μg/mL) Viability %   IC~50~ (µg/mL)                                                         
  ---------------------------- ------------------------------------------ ---------------- ------- ------- ------- ------- ------- ------- ----- ------
  **Doxorubicin (standard)**   2.08                                       3.36             4.86    6.51    11.04   19.38   24.82   28.86   100   0.36
  **2c**                       9.56                                       14.65            28.72   36.93   46.80   61.78   76.09   81.43   100   27.9
  **2d**                       14.96                                      25.37            35.18   46.85   62.34   76.82   84.17   90.64   100   56.1
  **5a**                       17.39                                      35.26            46.87   62.34   79.15   87.29   94.12   97.34   100   112
  **5b**                       5.72                                       12.46            21.79   30.69   35.28   41.63   48.76   62.81   100   7.46
  **5d**                       10.67                                      24.16            36.25   48.32   61.74   76.98   85.04   92.36   100   58.6
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###### 

Viability values and IC~50~ of assessed thiazolines and *Doxorubicin* against *colon carcinoma cells (HCT-116)* Cell Line.

  Sample Number                Sample Concentration (μg/mL) Viability %   IC~50~ (µg/mL)                                                         
  ---------------------------- ------------------------------------------ ---------------- ------- ------- ------- ------- ------- ------- ----- ------
  **Doxorubicin (standard)**   2.08                                       3.36             4.86    6.51    11.04   19.38   24.82   28.86   100   0.49
  **2c**                       16.72                                      25.46            33.95   40.67   46.98   69.41   84.02   92.37   100   29.1
  **2d**                       21.53                                      32.68            40.97   56.13   71.84   86.25   93.89   97.04   100   87.8
  **5b**                       8.94                                       15.36            23.21   31.05   38.92   45.18   57.85   71.06   100   12.6
  **5d**                       17.85                                      32.64            45.72   57.18   72.34   87.29   94.12   97.65   100   102
